Quarterly report pursuant to Section 13 or 15(d)

Net (Loss) Income Per Share (Schedule Of reconciliation of the net income (loss) per basic and diluted common share) (Details)

v3.22.1
Net (Loss) Income Per Share (Schedule Of reconciliation of the net income (loss) per basic and diluted common share) (Details) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2022
Mar. 31, 2021
Schedule of Earnings Per Share, Basic and Diluted [Line Items]            
Net (loss) income $ (14,177,830) $ (6,380,006) $ (2,845,981) $ 17,227,701 $ (20,557,836) $ 14,381,720
Basic weighted average common shares outstanding 80,052,504   75,175,077   80,037,675 72,717,621
Common stock purchase warrants           744,821
Total net effect of dilutive instruments           7,936,449
Diluted weighted average common shares outstanding 80,052,504   75,175,077   80,037,675 80,654,070
Net (loss) income per basic common share outstanding $ (0.18)   $ (0.04)   $ (0.26) $ 0.20
Net (loss) income per diluted common share outstanding $ (0.18)   $ (0.04)   $ (0.26) $ 0.18
Stock Options [Member]            
Schedule of Earnings Per Share, Basic and Diluted [Line Items]            
Stock options and appreciation rights           7,147,372
Stock Appreciation Rights (SARs) [Member]            
Schedule of Earnings Per Share, Basic and Diluted [Line Items]            
Stock options and appreciation rights           44,256